2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146149
    MAO-B-IN-11 192383-78-1 98%
    MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity.
    MAO-B-IN-11
  • HY-14614D
    S-Adenosyl-L-methionine iodide 3493-13-8
    S-Adenosyl-L-methionine (S-Adenosyl methionine) iodide is an orally active methyl group donor. S-Adenosyl-L-methionine iodide is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine iodide also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine iodide has the potential for, cancer, liver disease and osteoarthritis research.
    S-Adenosyl-L-methionine iodide
  • HY-146150
    MAO-B-IN-12 2394733-97-0 98%
    MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC50 of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity.
    MAO-B-IN-12
  • HY-146151
    γ-Secretase modulator 12 2204249-82-9 98%
    γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC50 of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice.
    γ-Secretase modulator 12
  • HY-146201
    PDE4B/7A-IN-1 2511632-25-8 98%
    PDE4B/7A-IN-1 (compound 7) is a PDE4B/PDE7A inhibitor (PDE4B, IC50=80.4 μM) and 5-HT1A/5-HT-7R antagonist. PDE4B/7A-IN-1 has membrane-penetrating activity and high metabolic stability. PDE4B/7A-IN-1 exhibits antidepressant properties in rat behavioral tests.
    PDE4B/7A-IN-1
  • HY-146251
    BuChE-IN-6 2003213-07-6 98%
    BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ42 self-aggregation.
    BuChE-IN-6
  • HY-146280
    mGAT3/4-IN-1 2556833-57-7 98%
    mGAT3/4-IN-1 (compound 19b) is a potent mGAT3/mGAT4 inhibitor, with pIC50 values of 5.31 and 5.24, respectively. mGAT3/4-IN-1 exhibits a significant tactile allodynia reduction in diabetic neuropathic mice.
    mGAT3/4-IN-1
  • HY-146281
    mGAT3/4-IN-2 2556833-68-0 98%
    mGAT3/4-IN-2 (compound 27b) is a potent mGAT3/mGAT4 inhibitor, with pIC50 values of 5.44 and 5.25, respectively.
    mGAT3/4-IN-2
  • HY-146282
    mGAT-IN-1 2556833-08-8 98%
    mGAT-IN-1 (compound 28) is a potent and non-selective GAT inhibitor. mGAT-IN-1 has a high inhibitory potency toward mGAT3, with an IC50 of 2.5 μM and pIC50 of 5.61.
    mGAT-IN-1
  • HY-146305
    α-Glucosidase-IN-4 2410538-67-7 98%
    α-Glucosidase-IN-4 is a reversible and mixed type α-glucosidase inhibitor with an IC50 of 12.98 μM, a KI of 27.02 μM, and a KIS of 13.65 μM, respectively.
    α-Glucosidase-IN-4
  • HY-146312
    AChE/BChE/MAO-B-IN-1 2416910-82-0 99.57%
    AChE/BChE/MAO-B-IN-1 is a reversible and non-time-dependent AChE, BChE and MAO-B inhibitor with IC50 values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively. AChE/BChE/MAO-B-IN-1 can cross the BBB and shows neuroprotective effects without cytotoxicity.
    AChE/BChE/MAO-B-IN-1
  • HY-146313
    BChE-IN-7 2416910-85-3 98%
    BChE-IN-7 (compound 13) is a potent, selective, BBB-penetrated and reversible AChE and BChE inhibitor, with an IC50 of 0.06 μM (BChE). BChE-IN-7 can protect neuronal-like cells from toxic Aβ-species.
    BChE-IN-7
  • HY-146314
    MAO-B-IN-9 2416910-88-6 99.70%
    MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC50 of 0.18 μM. MAO-B-IN-9 prevents Aβ1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ1-42 anti-aggregation effects. MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MAO-B-IN-9
  • HY-146315
    AChE/BChE-IN-6 2416910-94-4 98%
    AChE/BChE-IN-6 (compound 22) is a potent dual AChE/BChE inhibitor with IC50 values of 0.809 µM, 2.248 µM and > 100 µM for hBChE, hAChE and hMAO-B, respectively. AChE/BChE-IN-6 penetrates the blood-brain barrier (BBB). AChE/BChE-IN-6 can be used for Alzheimer’s disease (AD) research.
    AChE/BChE-IN-6
  • HY-146341
    FAAH-IN-5 1338575-38-4 98%
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
    FAAH-IN-5
  • HY-146342
    FAAH/MAGL-IN-3 2848719-34-4 98%
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.
    FAAH/MAGL-IN-3
  • HY-146347
    MAO-B-IN-10 2376710-36-8 98%
    MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC50 of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.
    MAO-B-IN-10
  • HY-146351
    HDAC-IN-38 2408123-36-2 98%
    HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5).
    HDAC-IN-38
  • HY-146383
    H3R antagonist 2 2970985-05-6 98%
    H3R antagonist 2 (Compound 23) is a multitarget histamine H3 receptor (H3R) antagonist with a Ki of 170 nM for hH3R . H3R antagonist 2 shows inhibitory effects with IC50 values of 180, 880 and 775 nM for acetylcholinesterase, butyrylcholinesterase and human monoamine oxidase B (hMAO B), respectively. H3R antagonist 2 shows favorable anti-neuropathic pain and memory-enhancing effects. H3R can across BBB.
    H3R antagonist 2
  • HY-146386
    SIRT5 inhibitor 2 340306-87-8 98%
    SIRT5 inhibitor 2 (compound 49) is a potent SIRT5 inhibitor with an IC50 value of 2.3 μM. SIRT5 inhibitor 2 has inhibitory activity against the SIRT5-dependent desuccinylation. SIRT5 inhibitor 2 can be used for researching cancer and neurodegenerative diseases.
    SIRT5 inhibitor 2
Cat. No. Product Name / Synonyms Application Reactivity